On Jun. 2, 2022, the U.S. National Institutes of Health announced that a large randomized, placebo-controlled clinical trial showed that treating adults hospitalized with COVID-19 with infliximab or abatacept ﾖ drugs widely used to treat certain autoimmune diseases ﾖ did not significantly shorten time to recovery but did substantially improved clinical status and reduced deaths.